Search results for "Amide"

showing 10 items of 3119 documents

Extreme duration exercise affects old and younger men differently.

2022

Aim & Methods: Extreme endurance exercise provides a valuable research model for understanding the adaptive metabolic response of older and younger individuals to intense physical activity. Here, we compare a wide range of metabolic and physiologic parameters in two cohorts of seven trained men, age 30 ± 5 years or age 65 ± 6 years, before and after the participants travelled ≈3000 km by bicycle over 15 days. Results: Over the 15-day exercise intervention, participants lost 2–3 kg fat mass with no significant change in body weight. V̇O2max did not change in younger cyclists, but decreased (p = 0.06) in the older cohort. The resting plasma FFA concentration decreased markedly in both gro…

AdultMalecyclingPhysiologyRestendurance exerciseMASSINTRAMYOCELLULAR CERAMIDE ACCUMULATIONH2O2 EMISSIONenergy metabolismHumansCONTROLLED TOURMuscle SkeletalExerciseTriglyceridesAgedaerobic fitnessMORTALITYagingBody WeightENERGY-EXPENDITUREfat oxidationMiddle AgedINSULINPHYSICAL-ACTIVITYMAXIMAL FAT OXIDATIONPhysical EnduranceSKELETAL-MUSCLEmuscle biopsySettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieActa physiologica (Oxford, England)
researchProduct

Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with …

2019

Background Conflicting data have been published as to the risk of cytomegalovirus (CMV) DNAemia and CMV disease in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide. Methods We conducted a multicenter retrospective study including 118 patients subjected to unmanipulated haplo-HSCT to further clarify this issue. An historic cohort comprising 165 patients undergoing other transplant modalities (HLA-matched related, matched unrelated or mismatched) was built for comparison purposes. Plasma CMV DNA monitoring was performed using two highly sensitive real-time PCR assays. Results Overall, the cumulative incidence of…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentCyclophosphamidemedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationYoung AdultInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryIncidenceIncidence (epidemiology)Hematopoietic Stem Cell Transplantationvirus diseasesRetrospective cohort studyCmv dnaemiaMiddle AgedViral Loadmedicine.diseasesurgical procedures operativeInfectious DiseasesSpainCytomegalovirus InfectionsDNA ViralCohortFemalebusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).

2019

Fabry's disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). Patients with amenable mutations can be treated with migalastat, a recently approved oral pharmacologic chaperone to increase endogenous alpha-Gal A activity. We assessed safety along with cardiovascular, renal, and patient-reported outcomes and disease biomarkers in a prospective observational multicenter study after 12 months of migalastat treatment under real-world conditions. Fifty-nine (28 females) patients (34 (57.6%) pretreated with enzyme replacement therapy) w…

AdultMalemedicine.medical_specialty1-DeoxynojirimycinTime FactorsGlobotriaosylceramideRenal function030226 pharmacology & pharmacyGastroenterologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMigalastatGermanymedicineClinical endpointHumansPharmacology (medical)Genetic Predisposition to DiseaseProspective StudiesPharmacologySphingolipidsVentricular Remodelingbusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry's diseaseFabry diseaseBlood pressureTreatment Outcomechemistry030220 oncology & carcinogenesisalpha-GalactosidaseMutationFabry DiseaseFemaleGlycolipidsbusinessBiomarkersGlomerular Filtration RateClinical pharmacology and therapeutics
researchProduct

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-media…

2011

Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels50  mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600  mg/day or placebo in …

AdultMalemedicine.medical_specialtyAdolescentBrachial ArteryDalcetrapibCoronary DiseaseAtherosclerosis CETP inhibition Endothelial function Flow-mediated dilatation ester transfer protein density-lipoprotein cholesterol off-target toxicity cardiovascular-disease dependent vasodilation coronary risk nitric-oxide torcetrapib atherosclerosis cetpModels BiologicalPlaceboschemistry.chemical_compoundYoung AdultDouble-Blind Methodmedicine.arteryInternal medicineCholesterylester transfer proteinmedicineHumansSulfhydryl CompoundsBrachial arteryLipoprotein cholesterolFlow mediated vasodilatationAgedRationalizationbiologybusiness.industryAnticholesteremic AgentsEstersGeneral MedicineCetp inhibitionMiddle AgedAmidesCoronary heart diseaseClinical trialVasodilationTreatment OutcomechemistryRegional Blood FlowResearch DesignCardiologybiology.proteinlipids (amino acids peptides and proteins)FemaleEndothelium VascularbusinessAlgorithms
researchProduct

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard…

2011

Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then…

AdultMalemedicine.medical_specialtyAdolescentCyclophosphamideImmunologyAzathioprineBehcet's diseaseRheumatologyPrednisoneInternal medicinemedicineHumansImmunology and AllergyAdverse effectAgedTumor Necrosis Factor-alphabusiness.industryBehcet SyndromeAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabSurgeryDiscontinuationBehçet’s disease - TNF alfa - InfliximabClinical trialTreatment OutcomeAntirheumatic AgentsFemalebusinessmedicine.drug
researchProduct

Determination of haemoglobin adducts of acrylamide and glycidamide in smoking and non-smoking persons of the general population

2005

Acrylamide (AA) is a food-borne toxicant suspected to be carcinogenic to humans. It is formed in the heating process of starch-containing food. Currently, there is a great discussion about the possible human health risks connected with the dietary uptake of acrylamide. Haemoglobin adducts of acrylamide and its oxidative metabolite glycidamide are both markers of biochemical effect. However, because glycidamide has a higher carcinogenic potency than acrylamide itself, the glycidamide adduct might mirror the genotoxicity better than acrylamide adducts. In order to gain more information about the human metabolism of acrylamide, we investigated a small group of persons for the effective interna…

AdultMalemedicine.medical_specialtyAdolescentMetabolitePopulationmedicine.disease_causeGas Chromatography-Mass SpectrometryHemoglobinschemistry.chemical_compoundGermanyInternal medicinemedicineHumansGlobineducationCarcinogenAgedAcrylamideAcrylamideseducation.field_of_studySmokingPublic Health Environmental and Occupational HealthValineMetabolismMiddle AgedEndocrinologychemistryBiochemistryAcrylamideEpoxy CompoundsFemaleBiomarkersGenotoxicityProtein BindingToxicantInternational Journal of Hygiene and Environmental Health
researchProduct

Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia

1999

BackgroundIn the treatment of panic disorder with agoraphobia, the efficacy of pharmacological, psychological and combined treatments has been established. Unanswered questions concern the relative efficacy of such treatments.AimsTo demonstrate that moclobemide and cognitive–behavioural therapy (CBT) are effective singly and more effective in combination.MethodFifty-five patients were randomly assigned to an eight-week treatment of: moclobemide plus CBT; moclobemide plus clinical management (‘psychological placebo’); placebo plus CBT; or placebo plus clinical management.ResultsComparisons between treatments revealed strong effects for CBT. Moclobemide with clinical management was not superi…

AdultMalemedicine.medical_specialtyAdolescentPanic Disorder with AgoraphobiaMoclobemidemedicine.medical_treatmentPlacebo-controlled studyPlacebobehavioral disciplines and activities03 medical and health sciences0302 clinical medicinemental disordersMoclobemidemedicineHumans030212 general & internal medicinePsychiatryAgoraphobiaAgedAnalysis of VarianceCognitive Behavioral TherapyPanicFearMiddle Agedmedicine.diseaseCombined Modality TherapyAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBenzamidesCognitive therapyPhysical therapyPanic DisorderPatient ComplianceFemalemedicine.symptomPsychologyAnxiety disorderFollow-Up Studiesmedicine.drugAgoraphobiaBritish Journal of Psychiatry
researchProduct

Radical surgery and different types of urinary diversion in patients with rhabdomyosarcoma of bladder or prostate--a single institution experience.

2013

Abstract Purpose In a retrospective study we analyzed the outcome of patients treated for rhabdomyosarcoma (RMS) of the bladder/prostate with special attention to radical surgery. Methods In 25 patients with genitourinary RMS (15 bladder/10 prostate) the median age at diagnosis was 4 years [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , and 8 patients had a stage II RMS, 12 stage III and 5 stage IV. In 19/25 (12 bladder/7 prostate), radical surgery and urinary diversion were performed. Urinary diversion comprised 2 continent anal diversions, 11 continent cutaneous diversions, 4 colon conduits and 2 urethral diversions (2 +…

AdultMalemedicine.medical_specialtyAdolescentUrologymedicine.medical_treatmentUrologyAnal CanalUrinary DiversionYoung AdultAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomaMedicineHumansRadical surgeryRhabdomyosarcomaChildCyclophosphamideRetrospective Studiesbusiness.industryGenitourinary systemUrinary diversionUrinary Reservoirs ContinentProstatic NeoplasmsSurgical Stomasmedicine.diseaseAppendixNeck of urinary bladdermedicine.anatomical_structureTreatment OutcomeUrinary Bladder NeoplasmsDoxorubicinVincristineChild PreschoolPediatrics Perinatology and Child HealthDactinomycinFemalePouchNeoplasm Recurrence LocalbusinessComplicationhuman activitiesFollow-Up StudiesJournal of pediatric urology
researchProduct

Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous…

1998

Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY). We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for…

AdultMalemedicine.medical_specialtyAllogeneic transplantationTransplantation ConditioningCyclophosphamidemedicine.medical_treatmentGastroenterologyRenal Dialysishemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansTransplantation HomologousAntineoplastic Agents AlkylatingCyclophosphamidePreparative RegimenBone Marrow TransplantationTransplantationChemotherapyNephrosclerosisbusiness.industryHematologyTotal body irradiationmedicine.diseaseSurgeryCase-Control StudiesKidney Failure ChronicHemodialysisbusinessWhole-Body Irradiationmedicine.drugKidney diseaseChronic myelogenous leukemiaBone marrow transplantation
researchProduct

Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins.

2001

Abstract PURPOSE: Elevated plasma concentrations of low-density lipoproteins (LDL) increase risk for coronary heart disease. However, lipoprotein profiles rich in small, dense LDL particles confer greater risk than those that mainly consist of large, buoyant LDL. This may be due, in part, to the greater oxidative susceptibility of small, dense LDL. In the current studies, we tested whether differences in the oxidative behavior of buoyant and dense LDL arise from differences in their immediate metabolic precursors, intermediate-density lipoproteins. SUBJECTS AND METHODS: We compared the properties of intermediate-density lipoproteins and buoyant and dense LDL subfractions in 9 subjects with …

AdultMalemedicine.medical_specialtyAntioxidantParinaric Acidmedicine.medical_treatmentOxidative phosphorylationAntioxidantsReference ValuesInternal medicineMedicineHumansPolyacrylamide gel electrophoresisFluorescent DyesIntermediate-density lipoproteinbusiness.industryGeneral MedicineLipoproteins LDLEndocrinologyPhenotypeFatty Acids Unsaturatedlipids (amino acids peptides and proteins)Electrophoresis Polyacrylamide GelFemaleUltracentrifugebusinessQuantitative analysis (chemistry)Oxidation-ReductionLipoproteinThe American journal of medicine
researchProduct